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Objectives: Pompe disease is a rare genetic disease produced by mutations in the
GAA gene leading to progressive skeletal and respiratory muscle weakness. T1-weighted
magnetic resonance imaging is useful to identify fatty replacement in skeletal muscles
of late-onset Pompe disease (LOPD) patients. Previous studies have shown that
replacement by fat correlates with worse results of muscle function tests. Our aim was to
investigate if fat replacement of muscles involved in the ventilation process correlated with
results of the spirometry and predicted respiratory muscle impairment in LOPD patients
over time.
Materials andMethods: We studied a cohort of 36 LOPD patients followed up annually
in our center for a period of 4 years. We quantified muscle fat replacement using Mercuri
score of the thoracic paraspinal and abdominal muscles and the pillars of the diaphragm.
We correlated the combined Mercuri scores of these areas with spirometry results and
the need of respiratory support.
Results: We found a statistically significant correlation (Spearman test, p < 0.05;
coefficient of correlation > 0.6) between forced vital capacity seated and lying and fat
fraction score of all muscle groups studied. The group of patients who needed respiratory
support had higher fat fraction scores than patients not requiring ventilatory support.
Higher fat replacement in these areas correlated with worse progression in spirometry
values over time.
Conclusions: Fat replacement of paraspinal, abdominal, and trunk muscles correlates
with results of spirometry and is able to predict worsening in respiratory muscle function
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tests that could lead to an emerging ventilatory dysfunction. Therefore, the identification
of fat replacement in these muscle groups should lead to a closer monitorization
of patients. Radiologic evaluation of diaphragm pillars in T1-weighted imaging axial
sequences could also be helpful to predict respiratory insufficiency.
Keywords: Pompe disease, glycogen storage disease type II, MRI, muscular MRI, respiratory insufficiency,
accessory respiratory muscles, diaphragm pillars
INTRODUCTION
Pompe disease or glycogen storage disease type II is a rare
genetic disease produced by mutations in the GAA gene
encoding the enzyme acid alpha glucosidase (AAG). This enzyme
catalyzes glycogen into glucose inside the lysosomes. Mutations
in the GAA gene lead to accumulation of lysosomes loaded
with glycogen and autophagic vacuoles inside cells in several
tissues but especially in skeletal, smooth, and heart muscles (1).
This accumulation triggers only partially known intracellular
molecular pathways leading to necrosis and substitution of
muscle fibers by fat and fibrous tissue that eventually produces
permanent skeletal and respiratory muscle weakness.
Pompe disease is differentiated in two main phenotypes.
In infantile-onset Pompe disease, symptoms start during the
first months of life and are characterized by hypotonia, general
muscle weakness, respiratory impairment, and hypertrophic
cardiomyopathy. This phenotype is very severe with an ominous
prognosis and is associated with a very low or absent
expression of AAG (2). In contrast, in late-onset Pompe
disease (LOPD), symptoms start in any moment after 1
year old, being characteristic a slowly progressive weakness
affecting proximal muscles of the limbs and/or axial muscles
associated or not with respiratory muscle involvement and
elevated creatine kinase (CK) values in blood tests in most
patients (2, 3). The clinical spectrum in LOPD is heterogeneous,
ranging from isolated asymptomatic hyperCKemia to severe
muscle weakness and respiratory insufficiency requiring invasive
ventilatory support. Enzymatic replacement therapy (ERT) with
alglucosidase alfa (Myozyme/Lumizyme R©, Sanofi-Genzyme,
Cambridge, MA, USA) is the only approved treatment for
this disease (4). A single placebo-controlled clinical trials and
several open-label studies have already shown the efficacy of ERT
maintaining muscle and respiratory function over time (5–8).
Respiratory impairment is a commonmanifestation of LOPD.
Approximately 60–80% of LOPD patients develop respiratory
insufficiency during their lifetime (9). Ventilation is a complex
process that involves several muscles of the trunk, pharynx, and
larynx to accomplish an adequate inspiration and expiration
cycle. Diaphragm and intercostal muscles are considered primary
respiratory muscles playing a key role expanding the thoracic
cavity during inspiration. Other muscles such as scalenus,
serratus, sternocleidomastoid, and pectoralis support inspiration
when diaphragm and intercostals are weak enough to not achieve
an appropriate inspiration (10, 11). Respiratory insufficiency in
LOPD patients is mainly produced by diaphragm dysfunction
that should be checked routinely with pulmonary function
test (PFT) using spirometry. A difference of 10% or more in
forced vital capacity (FVC) in sitting position compared to
lying is considered a sign of diaphragm muscle weakness (12).
Other parameters assessed with conventional spirometry include
maximal inspiratory pressure (MIP) that also correlates with
diaphragm performance. However, PFTs are often influenced by
patient’s motivation, and to obtain a perfect test is not always easy
from a technical point of view.
In recent years, muscle magnetic resonance imaging
(MRI) using T1-weighted imaging (T1w) has proved to be
useful identifying skeletal muscle fat replacement in several
neuromuscular diseases, including LOPD. Previous studies
have shown that trunk and lower limbs muscles are commonly
replaced by fat in LOPD patients and that the amount of fat
present in these muscles correlates with the degree of muscle
impairment measured using different muscle function tests
(13, 14). Therefore, muscle MRI could be considered a good
biomarker of muscle function in this disease useful to distinguish
between mild and severe patients (15). Based on these previous
results, we wondered if fat replacement of the muscles involved
in the ventilation process correlated with spirometry values
or predicted respiratory muscle impairment in LOPD patients
over time.
MATERIALS AND METHODS
Description of the Study Population and
PFT
This study was a prospective longitudinal cohort study involving
36 genetically confirmed LOPD patients performed at Hospital
de la Santa Creu i Sant Pau (HSCP) in Barcelona from December
2013 to June 2018. The clinical and genetic features of this
cohort have been previously described (15). All patients were seen
once per year, and the assessment included a clinical interview,
several muscle function tests, a conventional spirometry, and a
whole-body muscle MRI using T1w sequence. We obtained PFT
during the 4 years’ duration of the study, and MRI T1w whole
body during the first 3 years. On the fourth year, we changed
the MRI protocol, and only images of the lower limbs were
obtained, so we did not use those images in the present study.
The study was approved by the HSCP Ethics Committee, and all
participants signed a consent form. The study was registered in
ClinicalTrials.gov with the identifier NCT01914536.
Inclusion criteria for the study were (1) a diagnosis of
LOPD according to the recommendations made by the European
Pompe Consortium: reduced enzymatic activity on fibroblasts,
blood leukocytes or skeletal muscle and/or the presence of two
knownmutations in the GAA gene (16); (2) no contraindications
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for the MRI; and (3) willingness to complete muscle function test
and respiratory assessment. Asymptomatic patients who only had
isolated hyperCKemia without clear skeletal muscle weakness in
clinical examination or respiratory symptoms were also included.
The criteria requested by health authorities to approve ERT in
Spain vary from one region to another, but are commonly based
on the presence of skeletal and/or respiratory muscular weakness
in clinical examination. Isolated hyperCKemia associated or
not to fatigue or muscle pain is not considered a criterion to
start ERT.
Muscle function tests and spirometry were performed by two
physiotherapists with a long experience in the assessment of
neuromuscular patients (I.B., I.P.-H.). In terms of spirometry, we
measured FVC seated and lying andMIP andmaximal expiratory
FIGURE 1 | MRI T1w of three LOPD patients: (A,D,G) correspond to a patient with mild involvement; (B,E,H) correspond to a patient with moderate muscular
involvement; (C,F,I) correspond to a patient with severe muscular involvement. Yellow arrowheads point the muscles assessed. PM, pectoralis major; SR, serratus;
Ld, latissimus dorsi; RA, rectus abdominis; Mu, multifidus; Lt, longissimus thoracis; Ic, iliocostalis; Tr, trapezius; Ob, obliquus externus and internus; QL,
quadratus lumborum.
FIGURE 2 | MRI T1w abdominal sections of three LOPD patients. Yellow arrows point to both diaphragm pillars. In case (A), right and left diaphragm pillars are visible
and do not show fatty replacement (Mercuri score 0). In case (B), left diaphragm pillar is visible and partially infiltrated, whereas right diaphragm pillar is absent (left
pillar Mercuri score 3 points). In case (C), we can observe fully replaced diaphragm pillars at both sides (Mercuri score 4 points).
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pressure (MEP) with the Carefusion Microlab ML 3500 MK8
spirometer (Carefusion, Yorba Linda, CA, USA).
Muscle Imaging
The 36 LOPD patients were imaged in a 1.5-T field magnetic
resonance system (1.5-T Achieva, Philips, Eindhoven, the
Netherlands) at HSCSP in Barcelona during the whole duration
of the study. Patients were imaged in supine position with the legs
stretched out. Whole-body axial T1w images were obtained. The
images were analyzed by three members of our team (D. R.-L., C.
N.-P., J. D.-M.) who quantified fatty muscle replacement using
the modified version of the Mercuri score published by Dr.
Fischer (17): no fatty replacement: 0 point; mild fatty replacement
or traces of infiltration on T1w scores, 1 point; fatty replacement
in <50% of the muscle scores, 2 points; fatty replacement in
more than 50% of the muscle scores, 3 points; and end-stage
appearance with the whole muscle replaced by fatty tissue scores,
4 points.
We analyzed fat replacement of the so-called respiratory
accessory muscles both in the right and left sides of the
body as shown in Figure 1. We divided respiratory accessory
TABLE 1 | Clinical features of the cohort.














1 Female 38 50 47 MW – No No
2 Female 20 48 39 MW + RS 34 Yes (noninvasive) Yes (noninvasive)
3 Female – 26 No HyperCKemia – No No
4 Female 56 63 59 MW – No No
5 Female 20 45 42 MW – No No
6 Female 36 51 47 MW – No No
7 Male 62 66 67 MW + RS 67 No Yes (noninvasive)
8 Female 49 59 52 MW – No No
9 Female 29 55 48 MW – No No
10 Male 13 42 39 MW + RS 38 Yes (noninvasive) Yes (noninvasive)
11 Female 23 31 24 MW + RS 23 Yes (noninvasive) Yes (noninvasive)
12 Female 20 46 39 MW – No No
13 Male 43 47 45 MW + RS 44 Yes (noninvasive) Yes (noninvasive)
14 Male 41 51 45 MW + RS 50 Yes (noninvasive) Yes (noninvasive)
15 Female 35 51 46 MW + RS 46 Yes (noninvasive) Yes (noninvasive)
16 Male – 22 No HyperCKemia – No No
17 Male – 14 No HyperCKemia – No No
18 Female 40 65 64 MW – No No
19 Female 24 35 29 MW – No No
20 Female 29 40 40 MW + RS 39 Yes (noninvasive) Yes (noninvasive)
21 Female 20 52 45 MW – No No
22 Male 47 64 57 MW + RS 56 Yes (noninvasive) Yes (noninvasive)
23 Male 2 8 No HyperCKemia – No No
24 Female 42 57 55 MW + RS 54 Yes (noninvasive) Yes (noninvasive)
25 Male 41 46 43 MW + RS 43 Yes (noninvasive) Yes (noninvasive)
26 Male 35 51 51 MW + RS 49 Yes (noninvasive) Yes (noninvasive)
27 Male 35 51 No MW – No No
28 Male 20 43 43 MW – No No
29 Female 40 54 48 MW – No No
30 Male – 12 No HyperCKemia – No No
31 Male 49 51 No HyperCKemia +
OA.
– No No
32 Male 39 43 No MW – No No
33 Female 16 20 No HyperCKemia – No No
34 Female 28 39 No MW – No No
35 Female 35 35 No HyperCKemia – No No
36 Male 44 49 No HyperCKemia – No No
Age is expressed in years. HyperCKemia patients did not have other clinical manifestations except of patient 31. ERT, enzyme replacement therapy; MW, muscular weakness; RS,
respiratory symptoms; OA, obstructive apnea.
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TABLE 2 | Mean values of the compound MRI scores at every visit.
Visit 1, mean (SD) Visit 2, mean (SD) Visit 3, mean (SD)
Abdominal score 19.52 (12.5) 19.77 (12.5) 21.5 (11.86)
Paraspinal score 19.11 (11.17) 20.08 (11.4) 21.78 (10.77)
Thorax score 9.08 (9.57) 9.97 (9.53) 11.55 (10.16)
Global score 48.32 (29.78) 49.83 (30.58) 54.89 (29.60)
SD, standard deviation.
muscles in three groups: thoracic muscles, paraspinal muscles,
and abdominal muscles. We calculated a compound modified
Mercuri score of these areas adding the individual Mercuri score
for each of those muscles from both sides (left and right) and
eventually obtaining four compound scores:
• Thoracic muscle score: Serratus L (0–4) + serratus R (0–4) +
latissimus dorsi L (0–4)+ latissimus dorsi R (0–4)+ pectoralis
major L (0–4) + pectoralis major R (0–4) + scalenus L (0–4)
+ scalenus R (0–4) + trapezius L (0–4) + trapezius R (0–4).
This score ranged from 0 to 40.
• Paraspinal muscle score:Multifidus L (0–4)+multifidus R (0–
4) + longissimus thoracis L (0–4) + longissimus thoracis R
(0–4)+ quadratus lumborum L (0–4)+ quadratus lumborum
R (0–4)+ iliocostalis L (0–4)+ iliocostalis R (0–4). This score
ranged from 0 to 32
• Abdominal muscle score: Obliquus externus L (0–4)+ obli
quus externus R (0–4) + obliquus internus L (0–4) +
obliquus internus R (0–4) + transversus abdominis L (0–4) +
transversus abdominis R (0–4)+ rectus abdominis L (0–4) +
rectus abdominis R (0–4). This score ranged from 0 to 32.
• Global Score: Thoracic muscle score (0–40) + paraspinal
muscle score (0–32) + Abdominal muscle score (0–32). This
last score ranged from 0 to 104.
Furthermore, we assessed the involvement of the diaphragm by
analyzing fatty replacement of the diaphragm pillars, which are
two musculotendinous structures easily identifiable surrounding
the anterior lumbar spine as shown in Figure 2.
Statistics
We confirmed the scores obtained were normally distributed
using Kolmogorov–Smirnov test, and consequently, we used
parametric statistic studies to analyze the data. We used
Student t-test to study if the differences observed in the
fatty replacement scores obtained between ventilated and
nonventilated patients were significant. To analyze differences
observed over time in fatty replacement, we used a mixed
linear model and applied Greenhouse–Geisser test. We used
Pearson test to correlate respiratory measurements with the
degree of muscle involvement, and we considered that the
correlation was good if the correlation coefficient were higher
than 0.6. Hierarchical analysis and graphical representation as a
heatmap was performed using R software, V.3.1.3. Significance
was set up at p-values lower than 0.05. Statistical studies were
performed with SPSS for MAC computers (version 21, SPSS Inc.,
Chicago, IL).
TABLE 3 | Mean values of the MRI scores and Mercuri score of diaphragm pillars
classified in ventilated and nonventilated patients.
Noninvasive mechanical





Abdominal score 26.16 (6.8) 16.95 (13.62) 0.013
Paraspinal score 26.8 (3.68) 15.54 (11.94) 0.001
Thorax score 12.7 (9.16) 7.7 (9.64) 0.155
Global score 65.75 (14.32) 40.6 (32.53) 0.006
Diaphragm pillar left 2.66 (1.7) 1.2 (1.6) 0.036
Diaphragm pillar right 2.66 (1.7) 1.2 (1.6) 0.036




Clinical data of the 36 LOPD patients enrolled in the study
have been previously reported and are displayed in Table 1 (15).
Twenty patients were female (55.5%). Mean age of the patients
at the start of the study was 43.9 ± 14.8 years. At the baseline
visit, 23 patients were on ERT with Myozyme. One patient
(patient 7) started ERT during the follow-up. Mean duration
of ERT treatment at baseline was 4.30 ± 2.69 years. Eight
patients were considered asymptomatic as they only presented
hyperCKemia and were not receiving ERT. The most common
clinical feature of the cohort was muscular weakness involving
the lower limbs. Eleven patients needed noninvasive nocturnal
mechanical ventilation at the start of our study. Patient 7 started
noninvasive nocturnal mechanical ventilation during the study.
MRI T1w Analysis
Both abdominal and paraspinal muscles were more commonly
and severely affected than thoracic muscles in our cohort
as shown in Tables 2, 3 and in Figure 3. The muscles more
commonly replaced by fat were multifidus, longissimus,
iliocostalis, rectus abdominis, the oblique muscles and
transversus abdominis. Latissimus dorsi was the thoracic
muscle more common and severely affected, while there was a
clear heterogeneity in the involvement of the remaining thoracic
muscles among patients as shown in Figure 3. We observed
significant differences in the degree of muscle fat replacement
between ventilated and nonventilated patients in abdominal
and paraspinal muscles but not in thoracic muscles at baseline
(Table 3). It is noteworthy that the pillars of the diaphragm
were more severely affected in ventilated than in nonventilated
patients (Table 3) as shown in Figure 2. There was a significant
progressive increase in the degree of fat replacement of thoracic,
abdominal, and paraspinal muscles during the follow-up
(Greenhouse Geisser, p < 0.001). Interestingly, some of the
presymptomatic patients have mild signs of fatty replacement
especially in paraspinal and abdominal muscles. It is noteworthy
that one of the considered presymptomatic patients had more
consistent changes affecting also thoracic muscles. However, this
patient did not complain of any muscular symptom.
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FIGURE 3 | The heatmap shows the MRI Mercuri score value for all the muscles studied, the presence of muscular weakness (symptomatic) or hyperCKemia alone
(no symptomatic), its relationship with the FVC at base time, and the needs of noninvasive mechanical ventilation in every patient. FVC, forced vital capacity; MRI,
magnetic resonance imaging.
Pulmonary Function Test Analysis
There were significant differences in FVC percentage predicted
measured seated or lying between ventilated and nonventilated
patients (Student t-test, p = 0.001 for both measurements).
Moreover, we identified a significant difference in FVC
seated between baseline and last visit both in ventilated and
nonventilated patients (Table 4). We did not observe significant
differences in FVC in presymptomatic patients between baseline
and last visit. The MIP and MEP values at baseline visit were also
studied obtaining a mean MIP of 70.52 ± 28.95% and a mean
MEP 72.98± 31.77% in all the patients.
Correlation Test
We observed significant correlation between global, thoracic,
abdominal, and paraspinal scores and FVC percentage predicted
seated and lying at baseline. Additionally, there were significant
correlations between fat replacement of the diaphragm pillars
and FVC percentage predicted seated and lying and MIP
(Table 5).
We also observed a significant correlation between baseline
MRI score and changes in FVC percentage predicted after 3 years
of follow-up for global (p = 0.013, r = −0.506), abdominal p =
0.017, r = −0.602), and paraspinal (p = 0.013, r = −0.542) MRI
Score. Although significant, the correlations with thoracic MRI
score and fat replacement of the diaphragm pillar were low: r =
−0.233 and r =−0.437, respectively.
It is noteworthy that one of the patients ventilated (patient
24), with a clear diaphragmatic dysfunction characterized by a
drop in FVC when lying higher than 20%, had mild abdominal
but severe paraspinal fat replacement (abdominal score: 10,
paraspinal score: 28) and normal diaphragm pillars. Additionally,
we detected patients (patients 6, 9, 14, 29, and 31) who had mild
to moderate abdominal fat replacement with a severe paraspinal
fat replacement but with diaphragm pillars nonaffected and
who did not show diaphragm dysfunction (FVC Seated - FVC
lying <10%).
We want to highlight the individual case of patient 14 who
is a 51-year-old male patient who was already using nocturnal
ventilation when recruited in this study. The patient was
diagnosed as having sleep apnea 3 years before being recruited
and was on nocturnal ventilation 8 h per night at the beginning
of the study, and this remained unmodified the whole duration of
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the study. The predicted FVC seated was 78%, and the predicted
FVC lying was 83% at baseline. At last visit, predicted FVC seated
was 69%, and FVC lying was 64%. These differences were not
compatible with diaphragmatic dysfunction using the definition
mentioned above (a drop in FVC higher than 10% between
seating and lying), but a worsening tendency was noticed. In
this patient, muscle MRI showed a severe fatty replacement
of paraspinal and abdominal muscles that was not modified
throughout the whole duration of the study. We have included
an MRI of this patient at first visit in Figure 4. The MRI scores
measured for this patient on the baseline visit were 30 points in
abdominal score, 25 points in paraspinal score, and 18 points
in thoracic score, so the Global score at the first visit was of 73
points. In the last visit, we identified a very mild worsening in
paraspinal score (26 points) and in thoracic score (19 points)
remaining unchanged the abdominal score. The global score was
of 75 then.
DISCUSSION
In this study, we show that fat replacement of thoracic,
abdominal, and paraspinal muscles correlates with low values of
FVC percentage predicted both seated and lying in a large cohort
of LOPD patients. Additionally, fat replacement of abdominal
and paraspinal muscles predicted changes in FVC during the
follow-up in our cohort. These results suggest that identification
of fat replacement in these areas on the MRI should lead to a
closer monitorization of respiratory muscle function over time.
It is well known that LOPD patients have a selective
involvement of paraspinal, abdominal and proximal muscles of
the lower limbs in T1w MRI sequences (14, 15). Here we have
confirmed these previous results, but we have also found a good
correlation between fat replacement and results of respiratory
muscle function tests. It has been previously shown that the
degree of fat replacement in a muscle correlates with results of
specific function tests including assessment of muscle strength
using handheld dynamometry or even assessment of muscle
performance using timed tests such as the 6-min walking test
(18–20). Accordingly, it is not surprising that fat replacement of
the diaphragm or of the accessory respiratory muscles, such as
thoracic muscles, has a good correlation with FVC. However, we
have seen here that abdominal and paraspinal involvement is also
associated with FVC, and it predicts changes in this measure over
time. This also suggests that clinical examination findings such
as a distended abdominal wall, Beevor sign (cephalic umbilical
shift with abdominal muscular contraction due to abdominal
weakness), or axial weakness, which are a common finding in
LOPD, should also point to a closer monitorization of respiratory
function (21).
In concordance with these results, we have observed
significant differences in the degree of fat replacement between
ventilated and nonventilated LOPD patients, suggesting that fat
replacement of these muscles leads to a decrease in respiratory
muscle function and eventually to the need of nocturnal
respiratory support. All patients using noninvasive ventilation
had some degree of fatty replacement in diaphragm pillars,
TABLE 4 | Mean values of the FVC measured seated and mean values of the








79.98% (21.43) 73.42 % (25.34) 0.002
Nonventilated
patients (24)
88.23% (18.61) 80.94% (24.21) 0.017
Ventilated
patients (12)








11.51 (12.27) 8.46 (7.42) 0.107
Nonventilated
patients (24)
10.45 (11.48) 8.11 (6.71) 0.460
Ventilated
patients (12)
23. 16 (15.00) 11.00 (8.93) 0.057
We compared the mean values from the first and last visit (p-values in the last column).
FVC%, forced vital capacity percentage predicted; FVC% S-L, FVC% measured seated –
FVC% measured lying; SD, standard deviation.
TABLE 5 | Correlations found between the compound scores calculated and the
diaphragm pillar involvement and the FVC% seated and lying.
FVC% seated FVC% lying MIP MEP




p = 0.772 p = 0.135




























We are showing the results of the Pearson test: p-value and R value. FVC%, forced
vital capacity percentage predicted; MIP, maximal inspiratory pressure; MEP, maximal
expiratory pressure.
except patient 14, who despite being ventilated did not meet the
standard criteria of diaphragm dysfunction. Although diaphragm
pillar grading is not a standardized procedure, and there is a
wide variability between healthy volunteers and patients, we
consider it is a valid measure linked to clinical involvement of
the diaphragm.
We have identified significant differences in FVC between
baseline and last visit in symptomatic patients treated despite
being treated with ERT. Several other studies have also analyzed
the progression of FVC over time in LODP patients treated with
ERT, and the results are variable. Most of the studies coincide in
a positive effect of starting ERT on FVC, as this value remains
stable in most of the patients during the first 5 years of treatment
(5, 8, 22). However, a recent study including patients followed
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FIGURE 4 | MRI T1w of patient 14 at first visit. From left to right, first image corresponds to shoulder girdle level; second image corresponds to a thoracic level, and
third image corresponds to an abdominal level. Yellow arrows point to the pectoralis major (PM), serratus (SR), latissimus dorsi (Ld), rectus abdominis (RA), and
iliocostalis muscle (Ic). The MRI scores at this visit were 30 points in abdominal score, 25 points in paraspinal score, and 18 points in thoracic score. The Global score
was of 73 points.
up for 10 years identified a mean decrease of more than 10%
in FVC in patients treated, which is in agreement with our
results, which are supported by an increase in fat replacement of
respiratory muscles, suggesting that ERT is not able to completely
stop progression of respiratory muscle degeneration in Pompe
patients (7).
Other previous studies have identified a correlation between
fatty replacement of abdominal muscles and diaphragm using
computed tomography scan or MRI with spirometry results
(23). We have confirmed these previous results, and additionally,
we have also found a correlation with fatty replacement of
paraspinal and thoracic muscles such as scalenus, trapezius, and
pectoralis major. However, it is noteworthy that the correlation
between FVC and fatty replacement of thoracic muscles was low,
suggesting that they do not have a prominent role in respiratory
function in LOPD patients, which is probably more dependent of
the diaphragm and the abdominal muscles in these patients. Our
protocol of MRI included only axial images, which unfortunately
do not allow a good analysis of intercostalis muscles. We think
that coronal images should be obtained if these muscles want
to be analyzed. In recent years, several studies have also used
MRI to study diaphragm function, and they have elegantly shown
changes in morphology of thorax cavity and decrease in thorax
dynamics during inspiration and expiration in LOPD patients
(23–25). These results suggest a prominent involvement of the
diaphragm, which is also supported by the frequent finding of
a decrease in FVC percentage predicted higher than 10% when
patients are lying compared to FVC seating and by the results
of echography studies showing thinner diaphragms, which are
replaced by fat (11, 26). The biggest limitation of our study is that
we have used a semiquantitative scale to analyze fat replacement
that is observer dependent and that have several limitations to
identify consistent changes over time. At present, quantitative
muscle MRI techniques, such as Dixon, are available and have
demonstrated to identify better changes in fat replacement over
time (27–29). However, it is important to take into account that
Dixon studies of the trunk muscles are extremely challenging
because of the movement artifacts of this area during normal
respiration. To obtain images of good quality could be even
more difficult in patients with respiratory involvement and
orthopnea such as LOPD patients because the only way of
avoiding motion artifacts using Dixon in this body areas is asking
the patients to do repeated apneas that can last for 10–15 s
(15, 30).
In conclusion, fat replacement of paraspinal, abdominal,
and trunk muscles correlates with FVC percentage predicted
seated and lying and is able to predict worsening in respiratory
muscle function tests that could lead to an emerging ventilatory
dysfunction. Therefore, the identification of fat replacement in
these muscle groups should lead to a closer monitorization
of patients.
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